Papaverine-phentolamine and prostaglandin E1 versus papaverine-phentolamine alone for intracorporeal injection therapy: a clinical double-blind study

J Urol. 1995 Sep;154(3):1017-9.

Abstract

Purpose: A study was designed to compare intracorporeal injections of papaverine plus phentolamine (2-drug solution) and papaverine plus phentolamine and prostaglandin E1 (3-drug solution) for the treatment for impotence.

Materials and methods: A total of 20 impotent patients received intracorporeal injections of the 2-drug or 3-drug solution alternately during 2 sessions, and the quality and duration of erections were assessed.

Results: Of the patients 73% achieved a full erection with the 3-drug solution compared to 28% with the 2-drug solution. The average duration of erections was 57 minutes and 33.6 minutes, respectively. The complication rate was similar for the 2 treatments.

Conclusions: Papaverine plus phentolamine and prostaglandin E1 is superior to papaverine plus phentolamine alone for the treatment of impotence.

Publication types

  • Clinical Trial
  • Comparative Study
  • Controlled Clinical Trial

MeSH terms

  • Adult
  • Aged
  • Alprostadil / administration & dosage*
  • Double-Blind Method
  • Drug Combinations
  • Erectile Dysfunction / drug therapy*
  • Humans
  • Impotence, Vasculogenic / drug therapy
  • Injections
  • Male
  • Middle Aged
  • Papaverine / administration & dosage*
  • Penile Erection
  • Penis
  • Phentolamine / administration & dosage*

Substances

  • Drug Combinations
  • Papaverine
  • Alprostadil
  • Phentolamine